« Back to Record
Citation APA

Wildiers, H., Meyskens, T., Marreaud, S., Dal Lago, L., Vuylsteke, P., Curigliano, G., Waters, S., Brouwers, B., Meulemans, B., Sousa, B., Poncet, C., & Brain, E. (2022). Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 64, 100-111. doi:10.1016/j.breast.2022.05.004


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/375148

Wildiers, H., Meyskens, T., Marreaud, S., Dal Lago, L., Vuylsteke, P., Curigliano, G., Waters, S., Brouwers, B., Meulemans, B., Sousa, B., Poncet, C., & Brain, E. (2022). Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 64, 100-111. doi:10.1016/j.breast.2022.05.004